A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
← catalyst calendarNCT06054555 · readout in 523 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
633actual
Sites
180
Countries
Argentina, Bosnia and Herzegovina, Canada +28
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-02 | actual | When the study began enrolling |
| Primary completion | 2028-01-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-25 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Melanoma
Interventions
- Drug: ABP 206
- Drug: Nivolumab — also filed as OPDIVO®
Primary outcomes
what the primary-completion date above is the date OFObjective response by Week 49
measured Week 49
Objective response at Week 17
measured Week 17
Progression-free survival (PFS)
measured From Randomization until Follow-up or End of treatment (EOT) or Early termination (ET) (Approximately 105 Weeks)
Overall survival (OS)
measured From Randomization until Follow-up or EOT or ET (Approximately 105 Weeks)
Duration of response (DOR)
measured From Randomization until Follow-up or EOT or ET (Approximately 105 Weeks)
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed